The short version of melanotan-2 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-17. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Hypoglycemia, also known as "low blood sugar", is when blood sugar decreases to below normal levels. This may result in a variety of symptoms including clumsiness, trouble talking, confusion, loss of consciousness, seizures or death. A feeling of hunger, sweating, shakiness and weakness may also be present. Symptoms typically come on quickly. The most common cause of hypoglycemia is medications used to treat diabetes such as insulin and sulfonylureas. Risk is greater in diabetics who have eaten less than usual, exercised more than usual or have consumed alcohol. Other causes of hypoglycemia include kidney failure, certain tumors, such as insulinoma, liver disease, hypothyroidism, starvation, inborn error of metabolism, severe infections, reactive hypoglycemia and a number of drugs including alcohol. Low blood sugar may occur in otherwise healthy babies who have not eaten for a few hours.
Heroin for the purposes of pain relief involves administration using a syringe with a nebulizer tip by a physician. Heroin may be used for fractures, burns, finger-tip injuries, suturing, and wound re-dressing, but is inappropriate in head injuries.
Volatolomics is a development of metabolomics that studies volatile organic compounds (VOCs) emitted by a biological systems. Plant metabolomics is designed to study the overall changes in metabolites of plant samples and then conduct deep data mining and chemometric analysis. Specialized metabolites are considered components of plant defense systems biosynthesized in response to biotic and abiotic stresses. Metabolomics approaches have recently been used to assess the natural variance in metabolite content between individual plants, an approach with great potential for the improvement of the compositional quality of crops.
== Adverse effects == Side effects include sedation, dry mouth, drowsiness, increased appetite and weight gain. Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur.
Both these levels are raised to be close in energy to the 7s ones, high enough to possibly be chemically active. This would allow for the possibility of exotic nihonium compounds without lighter group 13 analogues. Periodic trends would predict nihonium to have an atomic radius larger than that of thallium due to it being one period further down the periodic table, but calculations suggest nihonium has an atomic radius of about 170 pm, the same as that of thallium, due to the relativistic stabilisation and contraction of its 7s and 7p1/2 orbitals. Thus, nihonium is expected to be much denser than thallium, with a predicted density of about 16 to 18 g/cm3 compared to thallium's 11.85 g/cm3, since nihonium atoms are heavier than thallium atoms but have the same volume. Bulk nihonium is expected to have a hexagonal close-packed crystal structure, like thallium. The melting and boiling points of nihonium have been predicted to be 430 °C and 1100 °C respectively, exceeding the values for indium and thallium, following periodic trends. Nihonium should have a bulk modulus of 20.8 GPa, about half that of thallium (43 GPa).
Sources: en.wikipedia.org
Many international Hardee's franchises are located in countries in the Middle East and Pakistan, most being owned and operated by Americana Group. The Americana Group opened the Middle East's first Hardee's restaurant in Kuwait in June 1980. As of 2016, there are over 300 Hardee's restaurants throughout Asia and the Middle East, specifically in Bahrain, Egypt, Iraq, Jordan, Kazakhstan, Kuwait, Lebanon, Oman, Palestine, Pakistan, Qatar, Saudi Arabia, United Arab Emirates, and plans to open in Israel. Singapore had a Hardee's franchise first opened in 1984, but the last three outlets closed in 1988. Hardee's opened a store in South Korea in 1990, but it pulled in 2004, due to poor performance. Hardee's also used to operate in Hong Kong, but it pulled out in 2006, due to licensing issues with its US parent. Specifically, in the Middle East, the Hardee's menu does not include any pork items and each beef is certified Halal due to religious and cultural beliefs. The same menu is offered at Hardee's locations in Pakistan, which opened its first location in the country in 2009 in Lahore. Hardee's currently has 18 locations in Pakistan, with six in Lahore, four in Karachi, two each in Islamabad and Rawalpindi and one each in Faisalabad, Bhera, Peshawar and Multan. In 2014, it opened a restaurant in Erbil, Iraqi Kurdistan. There is also a Hardee's location at Jomo Kenyatta International Airport in Nairobi.
=== 5: Electron carriers === The transmembrane electron transfer carriers in the membrane include two-electron carriers, such as the disulfide bond oxidoreductases (DsbB and DsbD in E. coli) as well as one-electron carriers such as NADPH oxidase. Often these redox proteins are not considered transport proteins.
P-glycoprotein (3.A.1.201.1) is a well-studied protein associated with multi-drug resistance. It belongs to the human ABCB (MDR/TAP) family and is also known as ABCB1 or MDR1 Pgp. MDR1 consists of a functional monomer with two transmembrane domains (TMD) and two nucleotide-binding domains (NBD). This protein can transport mainly cationic or electrically neutral substrates as well as a broad spectrum of amphiphilic substrates. The structure of the full-size ABCB1 monomer was obtained in the presence and absence of nucleotide using electron cryo crystallography. Without the nucleotide, the TMDs are approximately parallel and form a barrel surrounding a central pore, with the opening facing towards the extracellular side of the membrane and closed at the intracellular face. In the presence of the nonhydrolyzable ATP analog, AMP-PNP, the TMDs have a substantial reorganization with three clearly segregated domains. A central pore, which is enclosed between the TMDs, is slightly open towards the intracellular face with a gap between two domains allowing access of substrate from the lipid phase. Substantial repacking and possible rotation of the TM helices upon nucleotide binding suggests a helix rotation model for the transport mechanism.
=== Shortage === Global shortages of technetium-99m emerged in the late 2000s because two aging nuclear reactors (NRU and HFR) that provided about two-thirds of the world's supply of molybdenum-99, which itself has a half-life of only 2.75 days, were shut down repeatedly for extended maintenance periods. In May 2009, the Atomic Energy of Canada Limited announced the detection of a small leak of heavy water in the NRU reactor that remained out of service until completion of the repairs in August 2010. After the observation of gas bubble jets released from one of the deformations of primary cooling water circuits in August 2008, the HFR reactor was stopped for a thorough safety investigation. NRG received in February 2009 a temporary license to operate HFR only when necessary for medical radioisotope production. HFR stopped for repairs at the beginning of 2010 and was restarted in September 2010. Two replacement Canadian reactors (see MAPLE Reactor) constructed in the 1990s were closed before beginning operation, for safety reasons. A construction permit for a new production facility to be built in Columbia, MO was issued in May 2018.
Sources: en.wikipedia.org
=== Reports by the Western media === On 9 August 2008, the Associated Press reported that one Russian conscript said he was suddenly deployed to South Ossetia instead of expected exercises in North Ossetia. On 18 August 2008, Le Figaro published the report by journalist who was told by a young Russian soldier at some checkpoint in Georgia that he came from Shali, Chechen Republic and that they left on 5 August 2008. On 27 August 2008, the Financial Times quoted an unnamed Russian colonel as saying: "We were called to react to alarm on the night of 7th. [...] There was such an escalation of events that I cannot remember exactly when we entered the tunnel." On 29 August 2008, journalist Robert Parsons wrote in The Guardian that Russian servicemen deployed in Georgia had told him that they had been preparing for the war for weeks. In September 2008, The New York Times quoted anonymous American official as having stated that the western intelligence had information that two battalions of the 135th Regiment could have entered South Ossetia on the night of August 7. In May 2009, the United States Department of State official Matthew Bryza told Echo of Moscow that the United States knew that the Russian tank deployments to South Ossetia began in 2005 and these weaponry were used in August 2008 invasion. He confirmed that Russian tanks were entering South Ossetia before 7 August 2008, but he could not say the exact number of incoming Russian tanks on 7 August.
In its Guidance for Industry "Data Integrity and Compliance With Drug CGMP" US-FDA states "it is the role of management with executive responsibility to create a quality culture where employees understand that data integrity is an organizational core value and employees are encouraged to identify and promptly report data integrity issues." Australia's Therapeutic Goods Administration has said that recent data integrity failures have raised questions about the role of quality culture in driving behaviors. In addition, non-governmental organizations such as the International Society for Pharmaceutical Engineering (ISPE) and the Parenteral Drug Association (PDA) have developed information and resources to help pharmaceutical companies better understand why quality culture is important and how to assess the current situation within a site or organization.
The first reported protein synthesized by KAHA ligation was human GLP-1 (7-36). Since then, a variety of small proteins (up to 200 residues) have been synthesized, including ubiquitin and other similar modifier proteins, hormone proteins, nitrophorin 4, S100A4 and cyclic proteins. C-terminal ketoacid monomers are pre-loaded on resin via a linker for Fmoc-SPPS (Fmoc-based solid phase peptide synthesis). Initial research utilised sulfur ylide linkers, but more recently the group developed acid- and photo-labile ketoacid monomers that can be loaded directly on Rink Amide resin. The most commonly used N-terminal hydroxylamine is the 5-oxaproline, which results in a homoserine residue after ligation and O-N rearrangement.
== Research == Pentoxifylline is a synthetic methylxanthine derivative that is commonly used for peripheral vascular disease, but has also been researched as a possible treatment for Peyronie's disease. It's proposed to act through multiple mechanisms, including antioxidant, antifibrotic (including reducing TGF-β), and anti-inflammatory pathways, to interfere with the disease's pathogenesis and reduce symptoms such as penile curvature, pain, and plaque volume. While systematic reviews indicate a lack of consistent large-scale evidence for its efficacy, various clinical studies and case reports suggest that pentoxifylline, especially in combination with other therapies, may effectively reduce the progression of Peyronie's disease.
Early fossils that might represent animals appear for example in the 665-million-year-old rocks of the Trezona Formation of South Australia. These fossils are interpreted as most probably being early sponges. Trace fossils such as tracks and burrows found in the Tonian period (from 1 gya) may indicate the presence of triploblastic worm-like animals, roughly as large (about 5 mm wide) and complex as earthworms. However, similar tracks are produced by the giant single-celled protist Gromia sphaerica, so the Tonian trace fossils may not indicate early animal evolution. Around the same time, the layered mats of microorganisms called stromatolites decreased in diversity, perhaps due to grazing by newly evolved animals. Sterane biomarkers, which are usually indicative of demosponges, are found throughout the late Cryogenian and onward, but may also be produced by rhizarians. Objects such as sediment-filled tubes that resemble trace fossils of the burrows of wormlike animals have been found in 1.2 gya rocks in North America, in 1.5 gya rocks in Australia and North America, and in 1.7 gya rocks in Australia. Their interpretation as having an animal origin is disputed, as they might be water-escape or other structures.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.